Literature DB >> 26050977

Epidemiology of asthma in Poland in urban and rural areas, based on provided health care services.

Andrzej Śliwczyński1, Melania Brzozowska, Petre Iltchew, Tomasz Czeleko, Aleksandra Kucharczyk, Tadeusz Jędrzejczyk, Karina Jahnz-Różyk, Michał Marczak.   

Abstract

INTRODUCTION: Asthma is a serious health and social problem, also in Poland. The epidemiological data indicate that the problem of asthma concerns approximately 4 million people in Poland, whereas almost approximately 70% of them have no diagnosis and are not aware of their illness, and on the other hand in 39% of persons who declared the diagnosis of asthma in a survey the diagnosis was negatively verified (overdiagnosis of asthma). So far, no detailed comparative studies for asthma incidence rate in urban and rural areas were conducted in Poland. The aim of the study was to analyze patients with asthma in Poland in the years 2008-2012, with regard to province and type of commune (rural/urban).
MATERIAL AND METHODS: The study used data from National Health Fund (NFZ) - reported by health care providers regarding the patients diagnosed with asthma. Using structured query language (SQL) a set of patients was selected and created, for whom at the same time ICD-10 code: J45.X-bronchial asthma was reported. In order to estimate the number of patients with asthma we used the PESEL social security number as a unique identifier of the patient. Code of the patient's commune of residence in conjunction with the Central Statistical Office data formed the basis for the division of municipalities into urban and rural areas. The analysis of asthma incidence trends in Poland was performed on the basis of health services provided to patients. The analysis was performed by using the Statistica 10 software using a negative binomial regression model.
RESULTS: In 2009 a significant increase in the number of patients with asthma was observed compared with the previous year, whereas after 2009 the number of patients diagnosed with asthma remained relatively constant. A significant increase of predominance of women among asthma patients in recent years can be noticed: from 107% in 2008 to almost 115% in 2012 (F:M ratio). Regardless of the analyzed year and the diagnosis the incidence rate remained constant: approximately 55-57% for urban areas and about 43-45% in rural areas.
CONCLUSIONS: The average prevalence rate for rural areas is significantly lower than for urban areas. The use of adjusted incidence rate leads to the conclusion that the number of sufferers in urban areas is higher (about 10%) of the number of sufferers in the rural areas. The results of the analysis are consistent with information from previous studies in Poland and in the world.

Entities:  

Mesh:

Year:  2015        PMID: 26050977     DOI: 10.5603/PiAP.2015.0029

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  4 in total

1.  Epidemiology and direct costs of atopic dermatitis in Poland based on the National Health Fund register (2008-2017).

Authors:  Filip Raciborski; Karina Jahnz-Rozyk; Anna Kłak; Adam J Sybilski; Aleksandra M Grąbczewska; Melania Brzozowska; Andrzej M Śliwczyñski
Journal:  Postepy Dermatol Alergol       Date:  2018-10-19       Impact factor: 1.837

2.  Models for estimating and projecting global, regional and national prevalence and disease burden of asthma: a systematic review.

Authors:  Mohammad Romel Bhuia; Md Atiqul Islam; Bright I Nwaru; Christopher J Weir; Aziz Sheikh
Journal:  J Glob Health       Date:  2020-12-30       Impact factor: 4.413

3.  Recorded prevalence of nasal polyps increases with age.

Authors:  Filip Raciborski; Magdalena Arcimowicz; Bolesław Samoliñski; Wojciech Pinkas; Piotr Samel-Kowalik; Andrzej Śliwczyñski
Journal:  Postepy Dermatol Alergol       Date:  2020-10-13       Impact factor: 1.837

4.  Trends in the Epidemiology of Allergic Diseases of the Airways in Children Growing Up in an Urban Agglomeration.

Authors:  Marcel Mazur; Maria Czarnobilska; Wojciech Dyga; Ewa Czarnobilska
Journal:  J Clin Med       Date:  2022-04-14       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.